Cambridge Trust’s Intellia Therapeutics NTLA Stock Holding History

Cambridge Trust’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$55K	Hold	2,000	–	–	﹤0.01%	412
2023 Q4	$61K	Hold	2,000	–	–	﹤0.01%	401
2023 Q3	$63.2K	Sell	2,000 -1,322	-40%	-$51.3K	﹤0.01%	391
2023 Q2	$135K	Hold	3,322	–	–	0.01%	322
2023 Q1	$124K	Hold	3,322	–	–	0.01%	334
2022 Q4	$116K	Hold	3,322	–	–	0.01%	341
2022 Q3	$186K	Hold	3,322	–	–	0.01%	288
2022 Q2	$172K	Hold	3,322	–	–	0.01%	316
2022 Q1	$241K	Hold	3,322	–	–	0.01%	309
2021 Q4	$392K	Buy	+3,322	New	+$416K	0.01%	252
2021 Q3	–	Sell	-1,322	Closed	-$214K	–	277
2021 Q2	$214K	Buy	+1,322	New	+$103K	0.01%	263

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Cambridge Trust's NTLA Position: Q1 2024 in Review

Cambridge Trust held its Intellia Therapeutics (NTLA) position steady in Q1 2024 at 2,000 shares worth $55K. The position accounts for ﹤0.01% of the portfolio, ranked #412.

Cambridge Trust first reported a position in NTLA in Q2 2021 and has held it in 11 quarters since. The position peaked at $392K in Q4 2021. 285 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

Cambridge Trust held 2,000 shares of Intellia Therapeutics worth $55K as of Q1 2024.
Cambridge Trust left its Intellia Therapeutics share count unchanged in Q1 2024.
Intellia Therapeutics made up ﹤0.01% of Cambridge Trust's portfolio in Q1 2024, its #412 holding.
Cambridge Trust first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 11 quarters since.
Cambridge Trust's Intellia Therapeutics position peaked at $392K in Q4 2021.
285 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.